The pharmacokinetics and pharmacodynamics of remifentanil in volunteers with severe hepatic or renal dysfunction

Journal of Clinical Anesthesia

Volumn 8, Issue 3 SUPPL., 1996, Pages S88-S90

  Dershwitz, Mark ^a   Rosow, Carl E ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

pharmacodynamics; pharmacokinetics; Remifentanil

Indexed keywords

3 [4 METHOXYCARBONYL 4 (N PHENYLPROPIONAMIDO)PIPERIDINO]PROPIONIC ACID; REMIFENTANIL;

ANESTHESIA; AREA UNDER THE CURVE; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; LIVER DYSFUNCTION; LUNG MINUTE VOLUME; PRIORITY JOURNAL;

EID: 0029920571     PISSN: 09528180     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-8180(96)90020-3     Document Type: Conference Paper

References (4)

1. Cunningham FE, Hoke JF, Muir KT, James MK, Hoffman WE: Pharmacokinetic/pharmacodynamic evaluation of remifentanil, GR90291, and alfentanil. Anesthesiology 1995;83:A376.
2. Dershwitz M, Hoke JF, Rosow CE, et al: Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease. Anesthesiology (in press).
3. Shlugman D, Dufore S, Dershwitz M, Michalowski P, Hoke J, Muir KT, Rosow C, Glass PSA: Respiratory effects of remifentanil in subjects with severe renal impairment compared to matched controls. Anesthesiology 1994;81:A1417.
4. Hoke JF, Muir KT, Glass PSA, Shlugman D, Rosow CE, Dershwitz M, Michałowski P: Pharmacokinetics of remifentanil and its metabolite (GR90291) in subjects with renal disease. Clin Pharmacol Ther 1995;57:148.